Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Ovarian Neoplasms × Hydralazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 3 Refractory Solid Tumors 1 Ovarian Neoplasms 1 Locally Advanced Breast Cancer 1

Interventions

apatinib 3 pembrolizumab 2 Poly(ADP-ribose) Polymerase Inhibitors 2 Hyperthermic Intraperitoneal Chemotherapy 2 Bevacizumab 2 taxane 1 olaparib 1 lenvatinib 1 fludarabine 1 cediranib 1 Whole Genome Sequencing 1 Valproic Acid 1 Tranexamic Acid 1 Tai Ji 1 Surgical Procedures, Operative 1 Sequence Analysis, RNA 1 Saline Solution 1 Radiation 1 Qigong 1 Propranolol 1 Positron Emission Tomography Computed Tomography 1 Population Groups 1 Platinum 1 Paclitaxel 1 Neoadjuvant Therapy 1 Interleukin-2 1 Hydralazine 1 Gene Expression 1 Etoposide 1 Etodolac 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00533299 2007-09-21

Hydralazine Valproate for Ovarian Cancer

National Institute of Cancerología

Phase 3 Unknown

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡